Michel Obeid

Michel OBEID, M.D., Ph.D., PD-MERc, is considered one of the leading experts in the field of immuno-oncology toxicities.

Dr. Obeid has made numerous outstanding clinical research contributions that have led to significant improvements in the understanding of the pathogenesis mechanisms of immunotoxicities and the treatment of immune-related adverse events (irAEs), leading to the establishment of new imaging strategies for ICI-related myocarditis and the implementation of new personalized treatment approaches for refractory toxicities. Building on this international expertise, Dr. Obeid has led a principal role in the development of LCIT, the first pioneering center in Europe for the treatment of side effects related to cancer immunotherapy. One of his major focuses is the development of a second generation of immune checkpoint inhibitors (ICIs) able to attenuate tumor-derived immunosuppressive networks and substantially increase the proportion of responder patients to ICIs.

In the fundamental oncology field, Dr. Obeid’s earlier research represented a major contribution to identify new pharmacological targets to optimize cancer immunotherapy. He was a principal author in research that demonstrated the molecular characterization of tumor immunogenic cell death (ICD), which is capable of triggering anti-cancer immunity, by identifying two key molecular determinants in the cell surface translocation of calreticulin and ERP57. Based on these works, many pharmacological combination approaches have been developed to improve current oncology treatments.

Dr. Obeid completed his medical training and Ph.D. from the Universities of Paris Descartes and Paris Orsay. He obtained his PhD in immuno-oncology with honorable distinction for his distinguished works at the Institut Gustave Roussy on the immunogenic cell death. Then, He completed his clinical training in medical oncology in several outstanding institutions such Dana/Farber Cancer Institute and MD Anderson Cancer Center and in Switzerland. He also received the FMH in clinical immunology and allergy form Switzerland. Dr OBEID joined the INSERM at CIMI Center Paris as post-doctoral fellow and young research associate. Dr Obeid has multiple patients. Dr OBEID was appointed at the University of Lausanne in 2020 as Senior lecturer (privat-docent et maître d’enseignement et de recherche clinique).